U.S. Marine and Shipping Stock News

Savara (SVRA) is back in focus after the FDA accepted for review the biologics license application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis and granted it Priority Review with an August 22, 2026 action date. See our latest analysis for Savara. The FDA news arrives after a mixed few months for Savara, with a 1-day share price return of 2.23% and a 7-day share price return of 4.37%. However, the 90-day share price return shows a 5.09% decline, which contrasts with a...

Innoviva (INVA) has wrapped up FY 2025 with Q4 revenue of US$114.6 million and basic EPS of US$2.19, capping a trailing 12 month period where revenue was US$411.3 million and basic EPS reached US$4.02 alongside a reported net profit margin of 65.9% that was lifted by a US$161.6 million one off gain. Over the past few quarters, the company has seen revenue move from US$88.6 million in Q1 2025 to US$114.6 million in Q4 2025, while basic EPS shifted from a loss of US$0.74 in Q1 2025 to US$2.19...

PACS Group (NYSE:PACS) has filed a large shelf registration tied to an employee stock ownership plan related common stock offering. The filing outlines a framework for issuing a substantial amount of common shares to support ESOP activity over time. This move is designed to connect employee compensation more directly with the company’s equity. PACS Group operates in the post acute care and senior living space, where staffing, retention, and alignment of incentives are central issues for...

UK Information Commissioner's Office fines Reddit for failures in protecting children's personal data and privacy. Regulator cites insufficient age checks and risk assessments on the platform prior to January 2025. Reddit plans to appeal the decision, putting its data practices and user protections under closer scrutiny. For investors watching NYSE:RDDT, this case puts Reddit's content and data practices in the spotlight alongside its financial profile. The stock trades at $151.25, with a...

Impinj (PI) is back in focus after quarterly revenue landed in line with expectations, but management’s guidance for the coming quarter fell well short, citing inventory normalization, softer retail demand, and modest pricing pressure. See our latest analysis for Impinj. The weak guidance has already affected sentiment, with a 30 day share price return of negative 24.08% and a year to date share price return of negative 31.67%. At the same time, the 1 year total shareholder return is 34.37%,...

PostcardMania has launched an automated direct mail integration for HubSpot (NYSE:HUBS) users. The integration lets HubSpot customers trigger physical mailers directly from CRM workflows. The rollout connects digital campaigns with real world follow ups to address email saturation and engagement challenges. For HubSpot, which focuses on CRM, marketing automation and sales tools, this kind of direct mail automation fits into how many businesses already use the platform to manage the full...

Global Ship Lease recently went ex-dividend on February 24, 2026, entitling shareholders of record to receive a US$0.625 per share payout on March 6, 2026. This dividend timing and size can influence trading behavior, as some investors adjust positions around ex-dividend dates to pursue income-focused strategies. Now we’ll explore how this US$0.625 dividend and ex-dividend timing affect Global Ship Lease’s existing investment narrative and capital-return thesis. Invest in the nuclear...

Edison International (EIX) is back in focus after a mix of cautious analyst calls, a US$549.1 million fixed income raise, and detailed 2025 results paired with fresh earnings guidance through 2027. See our latest analysis for Edison International. The recent mix of earnings guidance, fresh bond issuance and ongoing wildfire related headlines has come alongside strong momentum. A 30 day share price return of 18.75% and a 1 year total shareholder return of 53.96% suggest interest has been...

Nomad Foods (NYSE:NOMD) closed FY 2025 with fourth quarter revenue of €773.1 million and a basic EPS loss of €0.07, capping a trailing twelve month revenue line of about €3.0 billion and EPS of €0.91 as margins compressed from a 7.3% net profit margin to 4.5% over the year. Over recent quarters, the company has seen quarterly revenue move from €793.4 million in Q4 2024 to €760.1 million in Q1 2025, €746.9 million in Q2 2025, €752.4 million in Q3 2025 and €773.1 million in Q4 2025. Basic EPS...

If you are wondering whether Huntington Bancshares is attractively priced at its current level, this article walks through what the numbers are really saying about the stock. The shares last closed at US$17.54, with a 7 day return of a 2.6% decline, a 30 day return of 2.8%, a year to date return of 0.3%, and a 1 year return of 10.6%, compared with 32.2% over 3 years and 34.9% over 5 years. Recent news coverage around regional banks has focused on how investors are weighing interest rate...

If you are wondering whether Ventas shares still offer value after a strong run, it becomes crucial to look closely at what you are paying for each dollar of cash flow and assets. The stock last closed at US$86.44, with returns of 1.1% over 7 days, 13.8% over 30 days, 11.8% year to date, 29.4% over 1 year, 99.7% over 3 years and 92.0% over 5 years. This naturally raises questions about how much optimism is already reflected in the price. Recent coverage of Ventas has focused on its position...

If you are wondering whether ZoomInfo Technologies' share price now reflects good value or lingering risks, you are not alone. That is exactly what this article will unpack for you. The stock recently closed at US$6.40, with returns of a 0.5% decline over 7 days, 26.6% decline over 30 days, 33.4% decline year to date, 46.7% decline over 1 year, 74.2% decline over 3 years, and 86.0% decline over 5 years. These figures raise clear questions about what investors are currently paying for. Recent...

In February 2026, Live Nation Entertainment reported full-year 2025 sales of US$25,201.41 million, upaction from US$23,155.63 million a year earlier, while net income fell to US$495.97 million and continuing operations shifted to a basic and diluted loss per share of US$0.24. Despite weaker profitability, the company’s expanding global venue footprint and continued growth in concert-driven revenue have reinforced analyst optimism about its long-term positioning in live entertainment. With...

EMCOR Group (EME) closed out FY 2025 with fourth quarter revenue of US$4.5b and basic EPS of US$9.72, alongside net income excluding extra items of US$434.6m, setting a clear marker for its latest reporting season. The company reported quarterly revenue of US$3.8b and EPS of US$6.35 in Q4 2024, rising to US$4.5b and EPS of US$9.72 in Q4 2025. Trailing twelve month EPS was US$28.30 on revenue of US$17.0b, giving investors a results set that combines higher earnings, a 7.5% net margin and prior...

Intro TG Therapeutics (TGTX) just closed out FY 2025 with Q4 revenue of US$192.6 million and basic EPS of US$0.16, alongside trailing twelve month revenue of US$616.3 million and EPS of US$3.10. Over the past couple of years, the company has reported revenue increasing from US$83.9 million in Q3 2024 to US$192.6 million in Q4 2025. Quarterly basic EPS has ranged from US$0.03 in Q1 2025 to US$2.69 in Q3 2025 and US$0.16 in the latest quarter, framing this release as a check-in on how durable...

Syndax Pharmaceuticals (SNDX) just reported Q4 2025 results that paired revenue ahead of expectations with a wider loss, as Revuforj net revenue grew 38% and Niktimvo sales continued to build. See our latest analysis for Syndax Pharmaceuticals. At a share price of US$20.67, Syndax has seen a 4.29% 90 day share price return and a 35.27% total shareholder return over the past year, suggesting momentum has been building despite some recent short term softness. If this update on a cancer focused...

PROG Holdings (NYSE:PRG) announced a 7.7% increase in its quarterly dividend, signaling confidence in returning cash to shareholders. The company is managing revenue pressure tied to a weaker retail backdrop and the bankruptcy of a major partner. Management has tightened Progressive Leasing criteria and is leaning more on its buy now, pay later platform and recent acquisitions. PROG Holdings enters this phase of corporate change with its shares at $36.83 and a mixed return profile. The...

AeroVironment (AVAV) drew fresh investor focus after securing a US$186 million delivery order from the U.S. Army for its next-generation Switchblade 600 Block 2 and 300 Block 20 loitering munitions. See our latest analysis for AeroVironment. Despite the new Army order and recent headlines around the BlueHalo acquisition and the CFO transition, AeroVironment’s 30 day share price return of 16.14% and 90 day return of 7.10% contrast with a 1 year total shareholder return of 70.96% and a roughly...

Franklin Resources (BEN) has been back on investors’ radar after its latest quarterly report showed earnings per share coming in ahead of analyst expectations. This has prompted fresh interest in how the asset manager is currently valued. See our latest analysis for Franklin Resources. The recent earnings surprise has come alongside a clear shift in sentiment around the share price, with Franklin Resources posting a 21.43% 90 day share price return and a 46.49% 1 year total shareholder...

Why Louisiana-Pacific Is On Investors’ Radar Today Louisiana-Pacific (LPX) is drawing attention after recent share moves, with the stock up about 1.4% over the past day but showing mixed performance over the past week and month. See our latest analysis for Louisiana-Pacific. The 1-day share price return of 1.45% comes after a softer patch. The 30-day share price return of 5.10% and 1-year total shareholder return decline of 14.97% signal that shorter term momentum has cooled, despite stronger...

Thermo Fisher Scientific (NYSE:TMO) has launched its TacroType Pharmacogenetic Test for transplant patients. The test is designed to help clinicians personalize tacrolimus dosing using a patient’s genetic profile. This product aims to support more tailored transplant care and potentially improve post transplant management. Thermo Fisher Scientific enters this launch with its shares at $520.12 and a value score of 4, along with mixed recent returns. The stock is up 1.0% over the past week,...

If you are wondering whether Cardinal Infrastructure Group is priced attractively today, you are not alone. The stock has been on many investors' watchlists as questions around its fair value grow louder. The share price sits at US$33.05, with returns of 2.5% over the last 7 days, 19.2% over the past 30 days, and 46.1% year to date. This has sharpened interest in what is actually built into the current valuation. Recent coverage has focused on Cardinal Infrastructure Group's role in the...

Recent performance snapshot for Waste Connections With no single headline event driving attention to Waste Connections (WCN) today, investors may be focusing on how the stock’s recent returns compare with its longer term track record and current business scale. The share price is roughly flat over the past month and shows a return of about 4% decline over the past 3 months, while year to date performance reflects about 3% decline. Over 1 year, total return stands near 8% decline, set against...

If you are wondering whether Crocs at around US$92.70 is a bargain or a trap, you are not alone. The stock has attracted a lot of attention from investors trying to work out what a fair price looks like. Recently, Crocs has had mixed share price returns, with a 3.9% decline over the last 7 days, a 10.2% gain over the last 30 days, a 6.6% gain year to date, an 8.1% decline over 1 year, a 26.0% decline over 3 years, and a 23.3% gain over 5 years. These moves have played out alongside ongoing...